Lihua Hou

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Shipo Wu, Jianying Huang, Zhe Zhang et al. · The Lancet Infectious Diseases · 2021 · 291 citations · Full text

A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

Shipo Wu, Gongxun Zhong, Jun Zhang et al. · Nature Communications · 2020 · 284 citations · Full text

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron et al. · The Lancet · 2021 · 230 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +8

Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial

Fengcai Zhu, Alie Wurie, Lihua Hou et al. · The Lancet · 2016 · 198 citations

Vaccination, Vaccine Safety, Vaccine Development +6

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

Jingxin Li, Lihua Hou, Xiling Guo et al. · Nature Medicine · 2022 · 158 citations · Full text